Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven T Chen

Showing results (91-100 of 153) with videos related to

Pageof 16
Sort By:
Journal of the American Academy of Dermatology|October 14, 2025
Vitamin D deficiency is associated with lower overall survival in patients receiving immune checkpoint inhibitors for cancer: A population-based cohort study using the TriNetX databaseNatalie Braun, Natalie Baker, Bryan L Peacker, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysisAmrita Goyal, Daniel O'Leary, Kavita Goyal, et al.
Journal of the American Academy of Dermatology|June 26, 2019
Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort studyAmrita Goyal, Daniel O'Leary, Kavita Goyal, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitorsMichael S Chang, Ted V Jacoby, Tracey S Otto, et al.
International Journal of Dermatology|March 21, 2025
Double Trouble: A Case Series on Dual Morphology Cutaneous Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint InhibitorsJoseph Ebriani, Mike Westmeijer, Bethany Brumbaugh, et al.
Cancer Medicine|July 10, 2019
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom controlMichael S Hughes, Hui Zheng, Leyre Zubiri, et al.
Journal of the American Academy of Dermatology|July 27, 2019
Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort studyGabriel E Molina, Ian M Allen, Michael S Hughes, et al.
Journal of the American Academy of Dermatology|October 17, 2025
Clinical presentation and survival outcomes of primary cutaneous T-cell lymphoma among disaggregated Asian American, Native Hawaiian, and Pacific Islander populationsDaniel Y Kim, Bryan L Peacker, Timothy M Dang, et al.
Journal of the American Academy of Dermatology|April 5, 2021
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysisShannon Wongvibulsin, Vartan Pahalyants, Mark Kalinich, et al.
The British Journal of Dermatology|March 15, 2022
Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapyTed V Jacoby, Tracey S Otto, Maria S Asdourian, et al.
Pageof 16

Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
Journal of the American Academy of Dermatology|October 14, 2025
Vitamin D deficiency is associated with lower overall survival in patients receiving immune checkpoint inhibitors for cancer: A population-based cohort study using the TriNetX databaseNatalie Braun, Natalie Baker, Bryan L Peacker, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysisAmrita Goyal, Daniel O'Leary, Kavita Goyal, et al.
Journal of the American Academy of Dermatology|June 26, 2019
Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort studyAmrita Goyal, Daniel O'Leary, Kavita Goyal, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitorsMichael S Chang, Ted V Jacoby, Tracey S Otto, et al.
International Journal of Dermatology|March 21, 2025
Double Trouble: A Case Series on Dual Morphology Cutaneous Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint InhibitorsJoseph Ebriani, Mike Westmeijer, Bethany Brumbaugh, et al.
Cancer Medicine|July 10, 2019
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom controlMichael S Hughes, Hui Zheng, Leyre Zubiri, et al.
Journal of the American Academy of Dermatology|July 27, 2019
Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort studyGabriel E Molina, Ian M Allen, Michael S Hughes, et al.
Journal of the American Academy of Dermatology|October 17, 2025
Clinical presentation and survival outcomes of primary cutaneous T-cell lymphoma among disaggregated Asian American, Native Hawaiian, and Pacific Islander populationsDaniel Y Kim, Bryan L Peacker, Timothy M Dang, et al.
Journal of the American Academy of Dermatology|April 5, 2021
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysisShannon Wongvibulsin, Vartan Pahalyants, Mark Kalinich, et al.
The British Journal of Dermatology|March 15, 2022
Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapyTed V Jacoby, Tracey S Otto, Maria S Asdourian, et al.
Pageof 16